Monster plaques: what they tell us about Alzheimer's disease? Nature Med - Yankner - 1998 () Citation Context ...een proposed and multiple molecular pathways can lead to AD, a central issue is whether the actions of these pathogenic factors could be conceptualized to converge into a common ...
BA test to tell if you are at risk from Alzheimer'sdisease(阿尔茨海默氏病)and dozens of other conditionsgoes on sale in Britain today costing f125.The test uses a saliva sample to provide more than 100pieces of genetic information including whether users aremore likely than normal to suffer ...
Through its attack on memory and other cognitive functions, Alzheimer's disease influences how people feel able to present themselves to others, and the way in which others respond. Studies asking people newly diagnosed with Alzheimer's disease about their concerns, suggest that many people fear ot...
What Your Doctor May Not Tell You About Alzheimer's Disease 电子书 读后感 评分☆☆☆ 评分☆☆☆ 评分☆☆☆ 评分☆☆☆ 评分☆☆☆ 类似图书 点击查看全场最低价 出版者:Grand Central Pub作者:Devi, Gayatri出品人:页数:320译者:出版时间:...
Sutherland - 《Current Alzheimer Research》 被引量: 85发表: 2009年 Increased CRMP2 phosphorylation is observed in Alzheimer's disease; does this tell us anything about disease development? Collapsin response mediator protein-2 (CRMP2) was recently identified as a physiological substrate for GSK3 ...
The range of memory impairments associated with Alzheimer's disease (AD) has been a focus for psychological and clinical researchers for many years. In addition to investigations of AD patients’ veridical memory using traditional recognition memory task
The galvanization of -amyloid in Alzheimer's disease why women more frequently develop Alzheimer's disease, and why rats and mice do not. Amyloid neuropathology of Alzheimer's disease is principally caused by... AI Bush,RE Tanzi - 《Proceedings of the National Academy of Sciences of the United...
Background Alzheimer's disease (AD) has a typical course characterizedby prominent memory impairment while Frontotemporal dementia (FTD)is characterized by early and prominentbehavioural/ personality/ executive function loss, and/or language problems.Many AD cases overlap clinically with (FTD). We wonder...
Howard Chertkow, James Nikelski, Ziad Nasreddine, Gabriel Leger - 2011 - S337-S338 - www.sciencedirect.comdoi:10.1016/j.jalz.2011.05.983Howard ChertkowJames NikelskiZiad NasreddineGabriel Leger
Despite affecting 55 million people worldwide, Alzheimer's disease still has no cure. But recent advancements in the field have seen a number of promising drugs that can slow the disease's progression pass late-stage clinical trials.